Monopoly concerns push FTC to sue to block Amgen’s more than $26B deal for Horizon
The U.S. is attempting to block the proposed acquisition of Horizon Therapeutics for more than $26 billion by biotech drug developer Amgen on antitrust grounds.
The Federal Trade Commission said Tuesday that the deal, announced in…